FDA Jan 10, 2023 Prenetics' ACT Genomics Profiling Test for Solid Tumors Receives FDA Clearance Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Dec 21, 2022 FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 19, 2022 FDA Updates Xeloda Labeling to Make DPYD Variant Risks More Explicit Dec 13, 2022 Amgen to Seek Blincyto Approval in MRD-Negative ALL Following Positive Phase III Results Premium Dec 13, 2022 FDA Approves Mirati's Krazati for Advanced KRAS-Mutated Lung Cancer Dec 7, 2022 FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Dec 5, 2022 Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting Dec 2, 2022 FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Nov 29, 2022 Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication Nov 22, 2022 Legend Biotech to Launch CAR T-Cell Therapy Trial for Small Cell Lung Cancer, Neuroendocrine Tumors Nov 21, 2022 Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial Nov 17, 2022 Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Premium Nov 17, 2022 Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators Nov 15, 2022 FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer Nov 11, 2022 J Ints Bio to Begin US Trial of JIN-A02 for EGFR C797S-Mutated NSCLC Nov 4, 2022 In Brief This Week: Omega Therapeutics, Rain Therapeutics, Oncoshot Oct 28, 2022 AbbVie, Genmab File for Bispecific Antibody Approval in US, EU for CD20-Positive Advanced Lymphoma Oct 28, 2022 In Brief This Week: Caris Life Sciences, Radiopharm Theranostics, Tempus Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer